SOLARAPharmaceuticals
Solara Active Pharma Sciences Ltd — Cash Flow Statement
₹425.55
-3.05%
Solara Active Pharma Sciences Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 172.88 Cr | 67.81 Cr | 44.94 Cr | -450.65 Cr | — |
| Repayment Of Debt | -110.95 Cr | -118.49 Cr | -130.62 Cr | -93.76 Cr | — |
| Issuance Of Debt | 75.00 Cr | 4.90 Cr | 68.30 Cr | 262.40 Cr | — |
| Issuance Of Capital Stock | 159.02 Cr | 0.00 | 0.00 | 2.90 Cr | — |
| Capital Expenditure | -39.94 Cr | -41.06 Cr | -111.31 Cr | -208.62 Cr | — |
| End Cash Position | 3.95 Cr | 8.44 Cr | 8.73 Cr | 46.38 Cr | — |
| Beginning Cash Position | 8.44 Cr | 8.73 Cr | 46.38 Cr | 197.69 Cr | — |
| Changes In Cash | -4.49 Cr | -0.29 Cr | -37.65 Cr | -151.31 Cr | — |
| Financing Cash Flow | -180.48 Cr | -105.65 Cr | -112.76 Cr | 333.57 Cr | — |
| Interest Paid Cff | -113.10 Cr | -102.63 Cr | -87.45 Cr | -73.40 Cr | — |
| Net Common Stock Issuance | 159.02 Cr | 0.00 | 0.00 | 2.90 Cr | — |
| Common Stock Issuance | 159.02 Cr | 0.00 | 0.00 | 2.90 Cr | — |
| Net Issuance Payments Of Debt | -221.38 Cr | -2.14 Cr | -22.88 Cr | 417.31 Cr | — |
| Net Short Term Debt Issuance | -185.43 Cr | 111.45 Cr | 39.44 Cr | 248.67 Cr | — |
| Net Long Term Debt Issuance | -35.95 Cr | -113.59 Cr | -62.32 Cr | 168.64 Cr | — |
| Long Term Debt Payments | -110.95 Cr | -118.49 Cr | -130.62 Cr | -93.76 Cr | — |
| Long Term Debt Issuance | 75.00 Cr | 4.90 Cr | 68.30 Cr | 262.40 Cr | — |
| Investing Cash Flow | -36.83 Cr | -3.51 Cr | -81.14 Cr | -242.85 Cr | — |
| Net Other Investing Changes | 1.02 Cr | 0.97 Cr | 5.15 Cr | 5.59 Cr | — |
| Interest Received Cfi | 0.75 Cr | 3.19 Cr | 7.35 Cr | 10.05 Cr | — |
| Net Business Purchase And Sale | 0.96 Cr | 0.00 | -1.28 Cr | 0.00 | — |
| Sale Of Business | 0.96 Cr | 0.00 | — | — | 0.00 |
| Net PPE Purchase And Sale | 0.38 Cr | 1.04 Cr | 1.30 Cr | 0.13 Cr | — |
| Sale Of PPE | 0.38 Cr | 1.04 Cr | 1.30 Cr | 0.13 Cr | — |
| Capital Expenditure Reported | -39.94 Cr | -41.06 Cr | -111.31 Cr | -208.62 Cr | — |
| Operating Cash Flow | 212.82 Cr | 108.87 Cr | 156.25 Cr | -242.03 Cr | — |
| Taxes Refund Paid | -0.90 Cr | 0.90 Cr | 13.54 Cr | -18.10 Cr | — |
| Change In Working Capital | 3.02 Cr | 190.63 Cr | 0.74 Cr | -313.79 Cr | — |
| Change In Other Current Liabilities | 10.86 Cr | 12.88 Cr | -25.00 Cr | 34.71 Cr | — |
| Change In Other Current Assets | -10.02 Cr | -20.80 Cr | 22.32 Cr | -29.49 Cr | — |
| Change In Payable | -59.43 Cr | 7.30 Cr | 38.90 Cr | -23.88 Cr | — |
| Change In Inventory | 41.80 Cr | 13.08 Cr | 17.32 Cr | -280.58 Cr | — |
| Change In Receivables | 19.81 Cr | 178.17 Cr | -52.80 Cr | -14.55 Cr | — |
| Other Non Cash Items | 108.60 Cr | 163.99 Cr | 66.39 Cr | 55.04 Cr | — |
| Stock Based Compensation | 2.68 Cr | 0.60 Cr | 0.05 Cr | -1.31 Cr | — |
| Provisionand Write Offof Assets | 1.02 Cr | 10.99 Cr | 5.66 Cr | 8.82 Cr | — |
| Depreciation And Amortization | 99.25 Cr | 103.33 Cr | 111.19 Cr | 112.32 Cr | — |
| Depreciation | 99.25 Cr | 103.33 Cr | 95.50 Cr | 97.05 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -1.47 Cr | -0.46 Cr | 3.05 Cr | 5.32 Cr | — |
| Gain Loss On Sale Of PPE | 0.00 | -0.36 Cr | 0.45 Cr | 0.77 Cr | — |
| Net Income From Continuing Operations | 0.54 Cr | -488.42 Cr | -44.82 Cr | -91.10 Cr | — |
| Purchase Of Business | — | 0.00 | -1.28 Cr | 0.00 | -0.10 Cr |
| Amortization Cash Flow | — | 13.24 Cr | 15.69 Cr | 15.27 Cr | 14.17 Cr |
| Purchase Of PPE | — | — | -111.31 Cr | -208.62 Cr | -174.48 Cr |
| Cash Dividends Paid | — | — | — | -10.78 Cr | -19.73 Cr |
| Net Investment Purchase And Sale | — | — | — | — | 50.00 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Solara Active Pharma Sciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.